Scholarlink

<p>The second edition of <i>Translational Neuroscience</i> offers wide-ranging and insightful perspectives on the effort to bring potentially revolutionary new classes of therapies to the clinic, thereby transforming the treatment of human nervous system disorders. Great advances in the fields of basic neuroscience, molecular biology, genomics, gene therapy, cell therapy, stem cell biology, information technology, rehabilitation, and others over the last 20 years have generated unprecedented opportunities to treat heretofore untreatable disorders of the nervous system. This book provides detailed coverage of these efforts, together with the methods for pursuing clinical translation and assessing clinical outcomes.&#xa0; All of the first edition chapters have been extensively updated, and many new chapters have been added, including brain-machine interface, gene therapy, anti-sense oligonucleotides, and CRISPR.&#xa0; &#xa0;Among the many other topics covered are Alzheimer’s disease, Parkinson’s disease, stroke, multiple sclerosis, epilepsy, motor neuron disease, pain, inborn errors of metabolism, brain tumors, spinal cord injury, neuroprosthetics, rehabilitation, and clinical trial design/consideration.</p><p><br></br></p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Translational Neuroscience

  • 书籍

  • 发表日期：

    2025年

查看全文

摘要

The second edition of Translational Neuroscience offers wide-ranging and insightful perspectives on the effort to bring potentially revolutionary new classes of therapies to the clinic, thereby transforming the treatment of human nervous system disorders. Great advances in the fields of basic neuroscience, molecular biology, genomics, gene therapy, cell therapy, stem cell biology, information technology, rehabilitation, and others over the last 20 years have generated unprecedented opportunities to treat heretofore untreatable disorders of the nervous system. This book provides detailed coverage of these efforts, together with the methods for pursuing clinical translation and assessing clinical outcomes.  All of the first edition chapters have been extensively updated, and many new chapters have been added, including brain-machine interface, gene therapy, anti-sense oligonucleotides, and CRISPR.   Among the many other topics covered are Alzheimer’s disease, Parkinson’s disease, stroke, multiple sclerosis, epilepsy, motor neuron disease, pain, inborn errors of metabolism, brain tumors, spinal cord injury, neuroprosthetics, rehabilitation, and clinical trial design/consideration.